Evidence map›Paper›PMID 24169147›Full record

Trial reportInternational psychogeriatrics2014

Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.

Krista L Lanctôt, Sarah A Chau, Nathan Herrmann, Lea T Drye, Paul B Rosenberg, Roberta W Scherer, Sandra E Black, Vijay Vaidya, David L Bachman, Jacobo E Mintzer

Open access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International psychogeriatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Medications for apathy in dementia.Canadian family physician Medecin de famille canadien · 2024
    Article
  10. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2023
    Article
  11. Review
  12. Review
  13. Article
  14. Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Krista L LanctôtDepartments of Psychiatry and Medicine (Neurology), and Brain Sciences Research Program, Sunnybrook Research Institute, Departments of Psychiatry, Pharmacology/Toxicology and Medicine (Neurology), University of Toronto, Ontario, Canada.
Sarah A ChauDepartments of Psychiatry and Medicine (Neurology), and Brain Sciences Research Program, Sunnybrook Research Institute, Departments of Psychiatry, Pharmacology/Toxicology and Medicine (Neurology), University of Toronto, Ontario, Canada.
Nathan HerrmannDepartments of Psychiatry and Medicine (Neurology), and Brain Sciences Research Program, Sunnybrook Research Institute, Departments of Psychiatry, Pharmacology/Toxicology and Medicine (Neurology), University of Toronto, Ontario, Canada.
Lea T DryeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Paul B RosenbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Roberta W SchererDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Sandra E BlackDepartments of Psychiatry and Medicine (Neurology), and Brain Sciences Research Program, Sunnybrook Research Institute, Departments of Psychiatry, Pharmacology/Toxicology and Medicine (Neurology), University of Toronto, Ontario, Canada.
Vijay VaidyaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
David L BachmanDepartment of Neurosciences, Alzheimer's Research and Clinical Programs, Medical University of South Carolina, SC, USA.
Jacobo E MintzerDepartment of Neurosciences, Alzheimer's Research and Clinical Programs, Medical University of South Carolina, SC, USA.
Johns Hopkins University · USUniversity of Toronto · CAMedical University of South Carolina · USRalph H. Johnson VA Medical Center · US

Funding

'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G · 1985 to 2019
$37.6M
Apathy in Alzheimer's Disease Methylphenidate TrialR01AG033032 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LANCTOT, KRISTA L., MINTZER, JACOBO · 2009 to 2010
$1.4M
PET imaging of activated microglia in Alzheimer's DiseaseK08AG029157 · NIA · JOHNS HOPKINS UNIVERSITY · PI ROSENBERG, PAUL B · 2008 to 2012
$539k
NIA NIH HHS 1 K08 AG029157-01A1NIA NIH HHS P50 AG005146NIA NIH HHS R01 AG033032NIA NIH HHS R01 AG033032-01
6 · The paper itself

Abstract

backgroundLittle is known about the effect of methylphenidate (MPH) on attention in Alzheimer's disease (AD). MPH has shown to improve apathy in AD, and both apathy and attention have been related to dopaminergic function. The goal was to investigate MPH effects on attention in AD and assess the relationship between attention and apathy responses.

methodsMPH (10 mg PO twice daily) or placebo was administered for six weeks in a randomized, double-blind trial in mild-to-moderate AD outpatients with apathy (Neuropsychiatric Inventory (NPI) Apathy ≥ 4). Attention was measured with the Wechsler Adult Intelligence Scale--Digit Span (DS) subtest (DS forward, selective attention) and apathy with the Apathy Evaluation Scale (AES). A mixed effects linear regression estimated the difference in change from baseline between treatment groups, defined as δ (MPH (DS week 6-DS baseline)) - (placebo (DS week 6-DS baseline)).

resultsIn 60 patients (37 females, age = 76 ± 8, Mini-Mental State Examination (MMSE) = 20 ± 5, NPI Apathy = 7 ± 2), the change in DS forward (δ = 0.87 (95% CI: 0.06-1.68), p = 0.03) and DS total (δ = 1.01 (95% CI: 0.09-1.93), p = 0.03) favored MPH over placebo. Of 57 completers, 17 patients had improved apathy (≥3.3 points on the AES from baseline to end point) and 40 did not. There were no significant associations between AES and NPI Apathy with DS change scores in the MPH, placebo, AES responder, or non-responder groups. DS scores did not predict apathy response to MPH treatment.

conclusionThese results suggest MPH can improve attention and apathy in AD; however, the effects appear independent in this population.

Indexed as

Alzheimer DiseaseMethylphenidateAgedAged, 80 and overApathyAttentionCentral Nervous System StimulantsDouble-Blind MethodDrug MonitoringFemaleHumansMaleNeuropsychological TestsPsychiatric Status Rating ScalesTreatment OutcomeCentral Nervous System StimulantsMethylphenidate

Identifiers

PMID24169147
PMCPMC3927455
OpenAlexW2169509396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.